Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) traded up 0.6% during trading on Tuesday . The company traded as high as $14.56 and last traded at $14.50, with a volume of 276,684 shares. The stock had previously closed at $14.41.

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. restated a “hold” rating and set a $16.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Thursday, May 5th. Needham & Company LLC restated a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday, May 4th. Cowen and Company restated a “market perform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, May 3rd. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Wedbush restated an “outperform” rating and set a $28.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Friday, May 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $18.50.

The firm has a 50 day moving average price of $13.88 and a 200-day moving average price of $12.20. The stock’s market capitalization is $1.51 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.04. During the same period in the previous year, the company earned ($0.04) EPS. The company earned $12.50 million during the quarter, compared to analyst estimates of $11.11 million. The company’s revenue was up 594.4% compared to the same quarter last year. On average, analysts anticipate that Lexicon Pharmaceuticals Inc. will post ($1.55) earnings per share for the current fiscal year.

In related news, VP James F. Tessmer sold 6,000 shares of the company’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $78,000.00. Following the completion of the sale, the vice president now owns 21,946 shares in the company, valued at $285,298. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Other large investors recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,372 shares in the last quarter. ProShare Advisors LLC increased its stake in Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 6,390 shares in the last quarter. Nationwide Fund Advisors increased its stake in Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 77,446 shares in the last quarter. New York State Common Retirement Fund increased its stake in Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock worth $2,358,000 after buying an additional 125,083 shares in the last quarter. Finally, Eagle Asset Management Inc. bought a new stake in Lexicon Pharmaceuticals during the fourth quarter worth approximately $8,426,000.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.